BRAF and colorectal carcinoma: Although few studies have investigated the impact of KRAS12 and KRAS13 mutations on CRC prognosis, a series of recent studies have highlighted the potential adverse prognostic impact of BRAF mutations, using both patients with stage II and III disease and patients across all disease stages (Ogino et al, 2009; Fariña-Sarasqueta et al, 2010).